Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22(10)
Oncotarget Oncotarget, 9(23), 16437-16450. Impact Journals Oncotarget 9 (2018): 16437–16450. doi:10.18632/oncotarget.24505 info:cnr-pdr/source/autori:Toffalorio F.; Santarpia M.; Radice D.; Jaramillo C.A.; Spitaleri G.; Manzotti M.; Catania C.; Jordheim L.P.; Pelosi G.; Peters G.J.; Tibaldi C.; Funel N.; Spaggiari L.; de Braud F.; De Pas T.; Giovannetti E./titolo:5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine%2Fplatinum combination chemotherapy in non-small cell lung cancer/doi:10.18632%2Foncotarget.24505/rivista:Oncotarget/anno:2018/pagina_da:16437/pagina_a:16450/intervallo_pagine:16437–16450/volume:9 Toffalorio, F, Santarpia, M, Radice, D, Jaramillo, C A, Spitaleri, G, Manzotti, M, Catania, C, Jordheim, L P, Pelosi, G, Peters, G J, Tibaldi, C, Funel, N, Spaggiari, L, de Braud, F, de Pas, T & Giovannetti, E 2018, ' 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer ', Oncotarget, vol. 9, no. 23, pp. 16437-16450 . https://doi.org/10.18632/oncotarget.24505